Late MCL Relapse Significantly Impacts Survival, Swedish Study Finds

A recent study is challenging long-held beliefs about mantle cell lymphoma (MCL), a type of blood cancer. Researchers have found that disease progression even years after initial treatment significantly impacts a patient’s survival, suggesting the conventional two-year mark for assessing risk may be insufficient.

Rethinking the Timeline for MCL Prognosis

The research, led by Sara Ekberg, PhD, of the Karolinska Institutet in Stockholm, analyzed data from 1186 patients diagnosed with MCL in Sweden between 2006 and 2018. Patients were followed for up to 10 years, and the findings were initially presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2025, with full publication anticipated in April 2026 in the International Journal of Cancer.

Treatment Approaches in the Study

The Swedish cohort received a variety of first-line treatments. Approximately 33% received bendamustine rituximab (BR), 30% received a regimen called Nordic MCL2—a combination of therapies including dose-escalated R-CHOP and high-dose treatment with stem cell transplantation—and 14% received R-CHOP or similar treatments. Other regimens, including those with ibrutinib, were also included in the overall analysis.

Did You Know? The study followed patients for up to 10 years after their initial diagnosis, revealing that disease progression more than six years after treatment remains a significant factor in survival.

Late Progression Carries Significant Risk

While early progression within 24 months of initial treatment has long been known to be a negative indicator, this study demonstrates that progression occurring 6 to 10 years after treatment also carries a significantly worse prognosis. Patients experiencing late disease progression faced more than a two-fold increased risk of mortality (HR, 2.67).

The impact of progression varied depending on the initial treatment received. Patients treated with the Nordic MCL2 regimen experienced the most dramatic impact from early progression—a 37-fold increased mortality risk within 12 months. However, even among patients receiving BR, those who progressed after 6 to 10 years faced a 5.6-fold increased risk.

Expert Insight: These findings underscore the importance of continued monitoring for MCL patients, even years after initial treatment, and suggest that strategies to prevent relapse—rather than solely focusing on prolonging remission—should be a priority.

Implications for Future Treatment Strategies

The study highlights the potential value of maintenance therapies and further investigation into the use of Bruton tyrosine kinase (BTK) inhibitors, potentially in combination with other drugs. Novel approaches, such as adding venetoclax to ibrutinib, may also improve outcomes for high-risk patients. Ongoing clinical trials are exploring combinations of BTK inhibitors and evaluating the efficacy of treatments like acalabrutinib, zanubrutinib, and pirtobrutinib.

Researchers emphasize the need to balance the intensification of treatment with potential long-term adverse effects. While more aggressive therapies may improve outcomes, they also carry risks of late toxicities and secondary malignancies, necessitating lifelong follow-up.

Frequently Asked Questions

What is mantle cell lymphoma?

Mantle cell lymphoma (MCL) is a type of B-cell malignancy, a cancer that starts in the lymphatic system.

How long were patients followed in this study?

Patients in the Swedish study were followed for up to 10 years after their initial diagnosis.

What is the significance of the 6-year mark in relation to MCL progression?

The study found that disease progression occurring more than 6 years after initial treatment still significantly impacts a patient’s survival, challenging the conventional focus on the first 24 months.

As treatment options for MCL continue to evolve, understanding the long-term implications of disease progression will be crucial for optimizing patient care. What role will ongoing research and clinical trials play in refining our approach to managing this challenging cancer?